306 related articles for article (PubMed ID: 28842137)
1. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
[TBL] [Abstract][Full Text] [Related]
2. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
[TBL] [Abstract][Full Text] [Related]
3. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.
Hans CP; Weisenburger DD; Vose JM; Hock LM; Lynch JC; Aoun P; Greiner TC; Chan WC; Bociek RG; Bierman PJ; Armitage JO
Blood; 2003 Mar; 101(6):2363-7. PubMed ID: 12424193
[TBL] [Abstract][Full Text] [Related]
4. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience.
Ganti AK; Weisenburger DD; Smith LM; Hans CP; Bociek RG; Bierman PJ; Vose JM; Armitage JO
Ann Oncol; 2006 Jun; 17(6):920-7. PubMed ID: 16524969
[TBL] [Abstract][Full Text] [Related]
5. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy.
Shustik J; Quinn M; Connors JM; Gascoyne RD; Skinnider B; Sehn LH
Ann Oncol; 2011 May; 22(5):1164-1169. PubMed ID: 21062969
[TBL] [Abstract][Full Text] [Related]
6. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
[TBL] [Abstract][Full Text] [Related]
8. High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.
Laurent C; Adélaïde J; Guille A; Tesson B; Gat E; Evrard S; Escudié F; Syrykh C; Canioni D; Fabiani B; Meignin V; Chassagne-Clement C; Dartigues P; Traverse-Glehen A; Parrens M; Huet S; Copie-Bergman C; Salles G; Birnbaum D; Brousset P; Morschhauser F; Xerri L;
Am J Surg Pathol; 2021 Oct; 45(10):1324-1336. PubMed ID: 34334687
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.
Horn H; Kohler C; Witzig R; Kreuz M; Leich E; Klapper W; Hummel M; Loeffler M; Trümper L; Spang R; Rosenwald A; Ott G;
Haematologica; 2018 Jul; 103(7):1182-1190. PubMed ID: 29567771
[TBL] [Abstract][Full Text] [Related]
12. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.
Rossi G; Marcheselli L; Dondi A; Bottelli C; Tucci A; Luminari S; Arcaini L; Merli M; Pulsoni A; Boccomini C; Puccini B; Micheletti M; Martinelli G; Rossi A; Zilioli VR; Bozzoli V; Balzarotti M; Bolis S; Cabras MG; Federico M
Am J Hematol; 2015 Jan; 90(1):56-61. PubMed ID: 25327841
[TBL] [Abstract][Full Text] [Related]
13. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.
Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS; Lu SC
Ann Hematol; 2012 Nov; 91(11):1741-5. PubMed ID: 22729139
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups.
Zhang F; Yan LX; Lin SX; Ye ZY; Zhuang HG; Yun JP; Lin HL; Luo DL; Xu FP; Luo XL; Cheng J; Zhang KP; Liu YH
Diagn Pathol; 2013 Sep; 8():154. PubMed ID: 24047469
[TBL] [Abstract][Full Text] [Related]
15. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases.
Rigacci L; Federico M; Martelli M; Zinzani PL; Cavanna L; Bellesi G; Merli F; Alterini R; Petrucci MT; Tani M; Liberati AM; Vitolo U; Pavone V; Cuneo A; Chisesib T; Brugiatelli M;
Leuk Lymphoma; 2003 Nov; 44(11):1911-7. PubMed ID: 14738142
[TBL] [Abstract][Full Text] [Related]
16. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.
Ayoub Z; Andraos T; Milgrom SA; Pinnix CC; Dabaja BS; Ng SP; Gunther JR; Khoury JD; Fowler NH; Neelapu SS; Samaniego F; Fayad LE; Nastoupil LJ
Leuk Lymphoma; 2019 Oct; 60(10):2432-2440. PubMed ID: 30942648
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
Južnič Šetina T; Borštnar S; Jezeršek Novaković B
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
[TBL] [Abstract][Full Text] [Related]
18. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
[TBL] [Abstract][Full Text] [Related]
19. A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
Bari A; Marcheselli R; Marcheselli L; Alvarez I; Pozzi S; Ferri P; Lazzaro A; Fragasso A; Neri S; Baldini L; Carella AM; Angrilli F; Guariglia R; Buda G; Stelitano C; Sacchi S;
Acta Haematol; 2017; 137(1):7-14. PubMed ID: 27820922
[TBL] [Abstract][Full Text] [Related]
20. Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource.
Wudhikarn K; Smith BJ; Button AM; Habermann TM; Thompson CA; Rosenstein LJ; Syrbu SI; Weiner GJ; Cerhan JR; Link BK
Leuk Lymphoma; 2015; 56(8):2365-72. PubMed ID: 25530345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
